Page 13 - Slide 1
P. 13
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1173 Femur QCT Analysis using MIAF in
Postmenopausal Women Treated with Odanacatib -
Results of a 2-year Placebo-controlled Trial.
Engelke K, Fuerst T, Dardzinski B, et al.
Concurrent Oral Session 29: Osteoporosis - Treatment
(Clinical) ◼ Monday, October 15, 11:00 AM - 11:15 AM ◼
Auditorium-Main/Minneapolis Convention Center
Results Abstract Information Additional Notes from
Poster/Presentation*
▪ Hip QCT scans at 2 years were
available for 78 women on ODN and 80 Updated/Additional Data,
women on placebo Key Takeaways
Conclusions ▪ Over a period of 2 years, ODN as
compared to placebo improves integral,
Implications trabecular and cortical BMD and BMC at
for Canadian femur relative to placebo.
Practice ▪ Cortical volume and thickness
significantly increased in all regions
except the neck.
Discussion Points, Key Takeaways
